会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • 당뇨망막병증의 조기 진단용 마커 및 이의 용도
    • 早期诊断糖尿病肾病的标记及其用途
    • KR1020130079952A
    • 2013-07-11
    • KR1020120000742
    • 2012-01-03
    • 서울대학교산학협력단
    • 김영수유형곤김경곤김상진유지영
    • G01N33/68C12Q1/68C12N15/11G01N33/53
    • G01N33/6893C12Q1/6883C12Q2600/158G01N33/5302G01N2800/042
    • PURPOSE: A marker for early diagnosis of diabetic retinopathy (DR) is provided to early diagnose DR and to significantly predict DR progression by measuring and comparing the expression level of genes or proteins of which expression is reduced in a patient with DR. CONSTITUTION: A composition for diagnosing DR contains an agent which measures mRNA level or protein level of one or more genes selected from the group consisting of prothrombin, apolipoprotein A1, alpha-2-macroglobulin, and complement factor H. A kit for diagnosing DR contains the composition. A method for providing information for diagnosing DR comprises the steps of: measuring the expression level of the genes or proteins selected from the group consisting of prothrombin, apolipoprotein A1, alpha-2-macroglobulin, and complement factor H; and comparing the expression level with the expression level of a control group sample.
    • 目的:提供早期诊断糖尿病视网膜病变(DR)的早期诊断指标,并通过测量和比较DR患者中表达降低的基因或蛋白质的表达水平来显着预测DR进展。 构成:用于诊断DR的组合物含有测定选自凝血酶原,载脂蛋白A1,α-2-巨球蛋白和补体因子H的一种或多种基因的mRNA水平或蛋白质水平的试剂。用于诊断DR的试剂盒包含 组成。 用于提供用于诊断DR的信息的方法包括以下步骤:测量选自凝血酶原,载脂蛋白A1,α-2-巨球蛋白和补体因子H的基因或蛋白质的表达水平; 并将表达水平与对照组样品的表达水平进行比较。
    • 2. 发明公开
    • 당뇨망막병증의 조기 진단용 마커 및 이의 용도
    • 早期诊断糖尿病肾病的标记及其用途
    • KR1020130079951A
    • 2013-07-11
    • KR1020120000741
    • 2012-01-03
    • 서울대학교산학협력단
    • 김영수유형곤김경곤김상진유지영
    • G01N33/68C12Q1/68G01N33/53
    • C12Q1/6883C12Q2600/158G01N33/6893G01N2800/042G01N2800/164G01N2800/50G01N2800/60G01N33/5302
    • PURPOSE: A marker for early diagnosis of diabetic retinopathy (DR) is provided to early diagnose DR and to significantly predict or understand DR progression by measuring and comparing the expression level of genes or proteins of which expression level is reduced in a patient with DR. CONSTITUTION: A composition for diagnosing DR contains an agent for measuring mRNA or protein level of one or more genes selected from the group consisting of prothrombin, apolipoprotein A1, alpha-2-macroglobulin, and complement factor H. A kit for diagnosing DR contains the composition. A method for providing information for diagnosing DR comprises the steps of: measuring the expression level of one or more genes or proteins selected from the group consisting of prothrombin, apolipoprotein A1, alpha-2-macroglobulin, and complement factor H; and comparing the expression level with the expression level of a control group sample.
    • 目的:提供早期诊断糖尿病性视网膜病变(DR)的标志物,以早期诊断DR,并通过测量和比较DR患者中表达水平降低的基因或蛋白质的表达水平来显着预测或了解DR进展。 构成:用于诊断DR的组合物含有用于测量选自凝血酶原,载脂蛋白A1,α-2-巨球蛋白和补体因子H的一种或多种基因的mRNA或蛋白质水平的试剂。用于诊断DR的试剂盒含有 组成。 提供用于诊断DR的信息的方法包括以下步骤:测量选自由凝血酶原,载脂蛋白A1,α-2-巨球蛋白和补体因子H组成的组中的一种或多种基因或蛋白质的表达水平; 并将表达水平与对照组样品的表达水平进行比较。
    • 4. 发明公开
    • 광학적 망막 특성 측정 장치
    • 用于测量RETINA光学特性的装置
    • KR1020120023902A
    • 2012-03-14
    • KR1020100086178
    • 2010-09-02
    • 서울대학교산학협력단
    • 유형곤김상진
    • A61B3/14A61B3/18A61B3/12
    • PURPOSE: An optical retinal property measurement apparatus is provided to compare blood vessel areas or branching angles by computing the blood vessel areas or the branching angles, thereby outputting quantitative retinal properties before and after performing an epiretinal membrane elimination process. CONSTITUTION: An eye-ground camera(110) records the bottom part of an eyeball. A first data storage device(120) stores a bottom part image of the eyeball. A blood vessel selection device(130) selects first and second major blood vessels. A second data storage device(140) two-dimensionally stores the first and second major blood vessels. A center detection device(150) determines the center of an optical disc or an eye socket. A quantitative retinal property calculation device calculates one or more among a blood vessel area and a branching angle.
    • 目的:提供光学视网膜性质测量装置,通过计算血管面积或分支角来比较血管面积或分支角度,从而在进行视网膜消除过程之前和之后输出定量视网膜特性。 构成:眼睛相机(110)记录眼球的底部。 第一数据存储装置(120)存储眼球的底部图像。 血管选择装置(130)选择第一和第二主要血管。 第二数据存储装置(140)二维地存储第一和第二主要血管。 中心检测装置(150)确定光盘或眼窝的中心。 定量视网膜特性计算装置计算血管区域和分支角度中的一个或多个。
    • 7. 发明授权
    • 당뇨병성 망막병증 검출용 바이오 마커 조성물 및 진단키트
    • 用于检测糖尿病性视网膜病变的生物标志物组合物及其诊断试剂盒
    • KR100961926B1
    • 2010-06-10
    • KR1020070087512
    • 2007-08-30
    • 서울대학교산학협력단
    • 김영수유형곤김상진김태오
    • C07K14/47
    • C07K14/47
    • 본 발명은 서열번호 1 내지 105의 아미노산 서열로 이루어진 단백질로부터 1 종 이상 선택된 단백질을 포함하는 당뇨병성 망막병증(diabetic retinopathy) 검출용 바이오 마커 조성물을 제공한다. 또한, 본 발명은 서열번호 1 내지 105의 아미노산 서열로 이루어진 단백질로부터 1 종 이상 선택된 단백질과 특이적으로 결합하는 분자를 포함하는, 당뇨병성 망막병증(diabetic retinopathy) 진단 키트를 제공한다.
      서열번호 1 내지 105의 아미노산 서열을 갖는 단백질은 PDR 환자에서 특이적으로 과량 발현되는 것으로 새롭게 밝혀진 단백질로서, 당뇨병성 망막병증을 검출할 수 있는 바이오 마커로서 사용될 수 있다. 따라서, 상기 바이오 마커는 당뇨병성 망막병증과 같은 유리체망막(vitreoretinal) 질환을 연구하는데 기초적인 정보를 제공할 수 있다. 특히, 상기 새롭게 밝혀진 단백질은 해당 단백질과 특이적으로 결합하는 분자, 예를 들어 모노클로날 항체 등과 함께 당뇨병성 망막병증의 진단을 위한 진단 키트로 제작될 수 있다.
      당뇨병성 망막병증, 바이오 마커
    • 10. 发明公开
    • 당뇨망막병증의 조기 진단용 마커 및 이의 용도
    • 早期诊断糖尿病肾病的标记及其用途
    • KR1020130079953A
    • 2013-07-11
    • KR1020120000743
    • 2012-01-03
    • 서울대학교산학협력단
    • 김영수유형곤김경곤김상진유지영
    • G01N33/68C12Q1/68G01N33/53
    • C12Q1/6883C12Q2600/158G01N33/6893G01N2800/042G01N2800/164G01N2800/50G01N2800/60G01N33/5302
    • PURPOSE: A marker for early diagnosis of diabetic retinopathy (DR) is provided to early diagnose DR and to significantly predict or understand DR progression by measuring and comparing the expression level of a gene or a protein of which expression is reduced in a patient with DR. CONSTITUTION: A composition for diagnosis of DR contains an agent which measures mRNA or protein level of one or more genes selected from the group consisting of alpha-1-acid glycoprotein 2, alpha-1-antitrypsin, apolipoprotein A2, apolipoprotein A4, beta-2-glycoprotein 1, and gelsolin. A kit for diagnosing DR contains the composition. A method for providing information for diagnosing DR comprises the steps of: measuring the expression level of one or more genes or proteins selected from the group consisting of alpha-1-acid-glycoprotein 2, alpha-1-antitrypsin, apolipoprotein A2, apolipoprotein A4, beta-2-glycoprotein 1, and gelsolin in a biological sample; and comparing the expression level with the expression level of a control group sample.
    • 目的:提供早期诊断糖尿病性视网膜病变(DR)的标志物,以早期诊断DR,并通过测量和比较DR患者中表达降低的基因或蛋白质的表达水平来显着预测或了解DR进展 。 构成:用于诊断DR的组合物含有测定一种或多种选自下组的基因或蛋白质水平的试剂:α-1-酸糖蛋白2,α-1-抗胰蛋白酶,载脂蛋白A2,载脂蛋白A4,β- 2-糖蛋白1和凝溶胶蛋白。 用于诊断DR的试剂盒包含组合物。 提供用于诊断DR的信息的方法包括以下步骤:测量一种或多种选自α-1-酸 - 糖蛋白2,α-1-抗胰蛋白酶,载脂蛋白A2,载脂蛋白A4的基因或蛋白质的表达水平 ,β-2-糖蛋白1和凝溶胶蛋白; 并将表达水平与对照组样品的表达水平进行比较。